礼来 13 亿联姻 AI 药企,筑牢肥胖症管线

生物制品圈
Aug 15

摘要:在新一代口服肥胖症药物 III 期数据不及预期后,制药巨头礼来(Eli Lilly)迅速出手,以 13 亿美元与波士顿 AI/机器学习初创公司 Superluminal Medicines 达成合作,聚焦 G 蛋白偶联受体(GPCRs)开发新型小分子肥胖症及 cardiometabolic 疾病药物。此次合作不仅延续了双方的合作渊源,更凸显礼来在肥胖症领域加码管线、应对市场竞争的迫切性。一、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10